Tianqi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tianqi Wang has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Hongqi Zhao
Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 shared publicationsXuan Fang
Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 shared publicationsJiyuan Yan
2 shared publications- Wei Seong Toh
National University of Singapore
2 shared publications Yi Zhang
2 shared publicationsZhong Li
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (5) , 102002
Purinergic signaling in osteoarthritis: Mechanistic insights into pathogenesis and therapeutic targeting
Osteoarthritis (OA) is a degenerative joint disease driven by a complex interplay of inflammation, extracellular matrix degradation, subchondral bone remodeling, and chronic pain. Purinergic signaling has emerged as a key regulator of OA pathogenesis, where dysregulated extracellular nucleotide-mediated P2 receptor activation and impaired adenosine-mediated P1 receptor signaling disrupt joint homeostasis. Excessive activation of P2X and P2Y receptors amplifies inflammatory cascades, promotes chondrocyte apoptosis, enhances matrix metalloproteinase activity, and sensitizes nociceptive pathways, while reduced P1 receptor signaling, particularly via A2A and A3, compromises anti-inflammatory and chondroprotective mechanisms. Additionally, disruptions in extracellular nucleotide metabolism exacerbate disease progression by perpetuating synovial fibrosis, cartilage destruction, and persistent pain. This review provides a mechanistic overview of purinergic receptor dysregulation in OA, detailing its roles in synovial inflammation, cartilage homeostasis, subchondral bone remodeling, and pain transmission. Furthermore, this review explores emerging therapeutic strategies targeting purinergic receptors, particularly P2 receptor antagonists and P1 receptor agonists, which are being developed as selective ligands to restore joint homeostasis and attenuate disease progression. Understanding the intricate molecular crosstalk between the P2 and P1 receptor pathways will be critical for the development of precision therapies aimed at modifying OA pathophysiology and improving clinical outcomes.
- 1 September 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (5) , 102002
Open AccessPurinergic signaling in osteoarthritis: Mechanistic insights into pathogenesis and therapeutic targeting
Osteoarthritis (OA) is a degenerative joint disease driven by a complex interplay of inflammation, extracellular matrix degradation, subchondral bone remodeling, and chronic pain. Purinergic signaling has emerged as a key regulator of OA pathogenesis, where dysregulated extracellular nucleotide-mediated P2 receptor activation and impaired adenosine-mediated P1 receptor signaling disrupt joint homeostasis. Excessive activation of P2X and P2Y receptors amplifies inflammatory cascades, promotes chondrocyte apoptosis, enhances matrix metalloproteinase activity, and sensitizes nociceptive pathways, while reduced P1 receptor signaling, particularly via A2A and A3, compromises anti-inflammatory and chondroprotective mechanisms. Additionally, disruptions in extracellular nucleotide metabolism exacerbate disease progression by perpetuating synovial fibrosis, cartilage destruction, and persistent pain. This review provides a mechanistic overview of purinergic receptor dysregulation in OA, detailing its roles in synovial inflammation, cartilage homeostasis, subchondral bone remodeling, and pain transmission. Furthermore, this review explores emerging therapeutic strategies targeting purinergic receptors, particularly P2 receptor antagonists and P1 receptor agonists, which are being developed as selective ligands to restore joint homeostasis and attenuate disease progression. Understanding the intricate molecular crosstalk between the P2 and P1 receptor pathways will be critical for the development of precision therapies aimed at modifying OA pathophysiology and improving clinical outcomes.
- Top Cited PapersOpen Access
- 3 April 2026
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 58, 101093
Mechanisms and precision interventions in sarcopenia and osteoarthritis comorbidity: A narrative review
- 3 April 2026
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 58, 101093
Top Cited PapersOpen AccessMechanisms and precision interventions in sarcopenia and osteoarthritis comorbidity: A narrative review
- Open Access
- 31 January 2026
- Published by Springer Nature in Advanced Composites and Hybrid Materials
- Vol. 9 (1)
Mitochondrial-targeted ROS scavenger delivery using selenium-doped layered double hydroxide nanocomposites for enhanced osteoarthritis therapy via inflammation suppression and macrophage metabolism reprogramming
- 31 January 2026
- Published by Springer Nature in Advanced Composites and Hybrid Materials
- Vol. 9 (1)
Open AccessMitochondrial-targeted ROS scavenger delivery using selenium-doped layered double hydroxide nanocomposites for enhanced osteoarthritis therapy via inflammation suppression and macrophage metabolism reprogramming
- Open Access
- 22 January 2025
- Published by Elsevier in Composites Part B: Engineering
- Vol. 294
Small extracellular vesicles from 3D PCL/HA scaffold-cultured and EMF-stimulated BMSCs promote lumbar fusion via PTEN/PI3K/AKT pathway
- 22 January 2025
- Published by Elsevier in Composites Part B: Engineering
- Vol. 294
Open AccessSmall extracellular vesicles from 3D PCL/HA scaffold-cultured and EMF-stimulated BMSCs promote lumbar fusion via PTEN/PI3K/AKT pathway
- Open Access
- 2 January 2025
- Published by Oxford University Press (OUP) in Burns & Trauma
- Vol. 13
Multi-omics analysis of small extracellular vesicles in osteoarthritis: bridging the gap between molecular insights and clinical applications
Osteoarthritis (OA) is a prevalent degenerative joint disorder with significant socioeconomic impact. Despite advances in understanding its pathophysiology, current therapeutic strategies remain largely palliative. Small extracellular vesicles (sEV) have emerged as crucial mediators of intercellular communication in joint tissues, offering new insights into OA pathogenesis and potential therapeutic targets. This review explores the application of multi-omics approaches to sEV research in OA, assessing how these advanced technologies are contributing to our understanding of the disease and their potential to revolutionize OA management. We discuss the latest findings on the role of sEV in OA, the applications of multi-omics technologies in deciphering sEV cargo, the progress toward clinical translation, and the challenges and opportunities in this field. By synthesizing current knowledge and identifying key research gaps, this review provides a roadmap for leveraging sEV multi-omics to bridge the gap between molecular discoveries and clinical applications in OA.
- 2 January 2025
- Published by Oxford University Press (OUP) in Burns & Trauma
- Vol. 13
Open AccessMulti-omics analysis of small extracellular vesicles in osteoarthritis: bridging the gap between molecular insights and clinical applications
Osteoarthritis (OA) is a prevalent degenerative joint disorder with significant socioeconomic impact. Despite advances in understanding its pathophysiology, current therapeutic strategies remain largely palliative. Small extracellular vesicles (sEV) have emerged as crucial mediators of intercellular communication in joint tissues, offering new insights into OA pathogenesis and potential therapeutic targets. This review explores the application of multi-omics approaches to sEV research in OA, assessing how these advanced technologies are contributing to our understanding of the disease and their potential to revolutionize OA management. We discuss the latest findings on the role of sEV in OA, the applications of multi-omics technologies in deciphering sEV cargo, the progress toward clinical translation, and the challenges and opportunities in this field. By synthesizing current knowledge and identifying key research gaps, this review provides a roadmap for leveraging sEV multi-omics to bridge the gap between molecular discoveries and clinical applications in OA.
- Open Access
- 29 September 2024
- Published by MDPI AG in Nanomaterials
- Vol. 14 (19) , 1572
2D MXene Nanosheets with ROS Scavenging Ability Effectively Delay Osteoarthritis Progression
MXenes nanosheets with high conductivity, hydrophilicity, and excellent reactive oxygen species (ROS) scavenging ability have shown promise in treating various degenerative diseases correlated with abnormal ROS accumulation. Herein, the therapeutic potential of Ti3C2Tx nanosheets, which is the most widely investigated MXene material, in delaying osteoarthritis (OA) progression is demonstrated. In vitro experiments indicate the strong ROS scavenging capacity of Ti3C2Tx nanosheets and their acceptable biocompatibility. Ti3C2Tx nanosheets effectively protect chondrocytes from cell death induced by oxidative stress. In addition, Ti3C2Tx nanosheets demonstrate a prominent anti-inflammatory effect and the ability to restore homeostasis between anabolic activities and catabolic activities in chondrocytes. Furthermore, RNA sequencing reveals the potential mechanism underlying the Ti3C2Tx nanosheet-mediated therapeutic effect. Finally, the in vivo curative effect of Ti3C2Tx nanosheets is verified using a rat OA model. Histological staining and immunohistochemical analyses indicate that Ti3C2Tx nanosheets effectively ameliorate OA progression. Conclusively, the in vitro and in vivo experiments suggest that Ti3C2Tx nanosheets could be a promising and effective option for OA treatment.
- 29 September 2024
- Published by MDPI AG in Nanomaterials
- Vol. 14 (19) , 1572
Open Access2D MXene Nanosheets with ROS Scavenging Ability Effectively Delay Osteoarthritis Progression
MXenes nanosheets with high conductivity, hydrophilicity, and excellent reactive oxygen species (ROS) scavenging ability have shown promise in treating various degenerative diseases correlated with abnormal ROS accumulation. Herein, the therapeutic potential of Ti3C2Tx nanosheets, which is the most widely investigated MXene material, in delaying osteoarthritis (OA) progression is demonstrated. In vitro experiments indicate the strong ROS scavenging capacity of Ti3C2Tx nanosheets and their acceptable biocompatibility. Ti3C2Tx nanosheets effectively protect chondrocytes from cell death induced by oxidative stress. In addition, Ti3C2Tx nanosheets demonstrate a prominent anti-inflammatory effect and the ability to restore homeostasis between anabolic activities and catabolic activities in chondrocytes. Furthermore, RNA sequencing reveals the potential mechanism underlying the Ti3C2Tx nanosheet-mediated therapeutic effect. Finally, the in vivo curative effect of Ti3C2Tx nanosheets is verified using a rat OA model. Histological staining and immunohistochemical analyses indicate that Ti3C2Tx nanosheets effectively ameliorate OA progression. Conclusively, the in vitro and in vivo experiments suggest that Ti3C2Tx nanosheets could be a promising and effective option for OA treatment.
- Open Access
- 25 August 2024
- Published by Wiley
Small extracellular vesicles from 3D PCL/HA scaffold-cultured and EMF-stimulated BMSCs promote lumbar fusion via PTEN/PI3K/AKT pathway
Chronic low back pain, typically managed through lumbar fusion, demands innovative approaches to enhance therapeutic outcomes. This study investigates the efficacy of small extracellular vesicles (sEVs) derived from bone marrow mesenchymal stem cells (BMSCs) cultured in three-dimensional (3D) scaffolds concurrently under electromagnetic fields (EMF) stimulation, aiming to enhance osteogenesis and angiogenesis in a rat lumbar fusion model. We utilize a composite of polycaprolactone and hydroxyapatite, engineered via 3D printing, to create the scaffolds. sEVs are harvested from BMSCs under three distinct conditions: standard 2D cultures, 3D scaffolds, and 3D scaffolds with EMF stimulation. Specifically, the sEVs from the EMF-stimulated 3D cultures (3D/E-sEVs) are incorporated into these scaffolds before being implanted into rat spines. Results reveal that 3D/E-sEVs markedly enhance both osteogenesis and angiogenesis. Further mechanistic investigations identify the PTEN/PI3K/AKT signalling pathway as essential in mediating these regenerative effects. Moreover, 3D PCL/HA scaffold loaded with 3D/E-sEVs promote lumbar fusion in a rat model. Conclusively, our findings demonstrate that 3D-printed PCL/HA scaffolds engineered with 3D/E-sEVs significantly promote bone regeneration and vascular formation, thereby improving lumbar fusion outcomes. This study highlights potential of integrating tissue engineering techniques with sEVs therapies to revolutionize the treatment of low back pain and enhance surgical success rates.
- 25 August 2024
- Published by Wiley
Open AccessSmall extracellular vesicles from 3D PCL/HA scaffold-cultured and EMF-stimulated BMSCs promote lumbar fusion via PTEN/PI3K/AKT pathway
Chronic low back pain, typically managed through lumbar fusion, demands innovative approaches to enhance therapeutic outcomes. This study investigates the efficacy of small extracellular vesicles (sEVs) derived from bone marrow mesenchymal stem cells (BMSCs) cultured in three-dimensional (3D) scaffolds concurrently under electromagnetic fields (EMF) stimulation, aiming to enhance osteogenesis and angiogenesis in a rat lumbar fusion model. We utilize a composite of polycaprolactone and hydroxyapatite, engineered via 3D printing, to create the scaffolds. sEVs are harvested from BMSCs under three distinct conditions: standard 2D cultures, 3D scaffolds, and 3D scaffolds with EMF stimulation. Specifically, the sEVs from the EMF-stimulated 3D cultures (3D/E-sEVs) are incorporated into these scaffolds before being implanted into rat spines. Results reveal that 3D/E-sEVs markedly enhance both osteogenesis and angiogenesis. Further mechanistic investigations identify the PTEN/PI3K/AKT signalling pathway as essential in mediating these regenerative effects. Moreover, 3D PCL/HA scaffold loaded with 3D/E-sEVs promote lumbar fusion in a rat model. Conclusively, our findings demonstrate that 3D-printed PCL/HA scaffolds engineered with 3D/E-sEVs significantly promote bone regeneration and vascular formation, thereby improving lumbar fusion outcomes. This study highlights potential of integrating tissue engineering techniques with sEVs therapies to revolutionize the treatment of low back pain and enhance surgical success rates.